295 related articles for article (PubMed ID: 30455685)
1. The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes.
Cruz-Leal Y; Grubaugh D; Nogueira CV; Lopetegui-González I; Del Valle A; Escalona F; Laborde RJ; Alvarez C; Fernández LE; Starnbach MN; Higgins DE; Lanio ME
Front Immunol; 2018; 9():2473. PubMed ID: 30455685
[TBL] [Abstract][Full Text] [Related]
2. Novel Adjuvant Based on the Pore-Forming Protein Sticholysin II Encapsulated into Liposomes Effectively Enhances the Antigen-Specific CTL-Mediated Immune Response.
Laborde RJ; Sanchez-Ferras O; Luzardo MC; Cruz-Leal Y; Fernández A; Mesa C; Oliver L; Canet L; Abreu-Butin L; Nogueira CV; Tejuca M; Pazos F; Álvarez C; Alonso ME; Longo-Maugéri IM; Starnbach MN; Higgins DE; Fernández LE; Lanio ME
J Immunol; 2017 Apr; 198(7):2772-2784. PubMed ID: 28258198
[TBL] [Abstract][Full Text] [Related]
3. Sticholysin II shows similar immunostimulatory properties to LLO stimulating dendritic cells and MHC-I restricted T cell responses of heterologous antigen.
Del Valle A; Acosta-Rivero N; Laborde RJ; Cruz-Leal Y; Cabezas S; Luzardo MC; Alvarez C; Labrada M; Rodríguez A; Rodríguez GL; Raymond J; Nogueira CV; Grubaugh D; Fernández LE; Higgins D; Lanio ME
Toxicon; 2021 Sep; 200():38-47. PubMed ID: 34237340
[TBL] [Abstract][Full Text] [Related]
4. Sticholysins, pore-forming proteins from a marine anemone can induce maturation of dendritic cells through a TLR4 dependent-pathway.
Laborde RJ; Ishimura ME; Abreu-Butin L; Nogueira CV; Grubaugh D; Cruz-Leal Y; Luzardo MC; Fernández A; Mesa C; Pazos F; Álvarez C; Alonso ME; Starnbach MN; Higgins DE; Fernández LE; Longo-Maugéri IM; Lanio ME
Mol Immunol; 2021 Mar; 131():144-154. PubMed ID: 33422341
[TBL] [Abstract][Full Text] [Related]
5. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
Song C; Noh YW; Lim YT
Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
[TBL] [Abstract][Full Text] [Related]
6. CD8- dendritic cells and macrophages cross-present poly(D,L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo.
Schliehe C; Redaelli C; Engelhardt S; Fehlings M; Mueller M; van Rooijen N; Thiry M; Hildner K; Weller H; Groettrup M
J Immunol; 2011 Sep; 187(5):2112-21. PubMed ID: 21795597
[TBL] [Abstract][Full Text] [Related]
7. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
Krishnan L; Sad S; Patel GB; Sprott GD
J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
[TBL] [Abstract][Full Text] [Related]
8. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population.
Wu CC; Liu SJ; Chen HW; Shen KY; Leng CH
Oncotarget; 2016 May; 7(21):30804-19. PubMed ID: 27127171
[TBL] [Abstract][Full Text] [Related]
9. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity.
Celluzzi CM; Falo LD
J Invest Dermatol; 1997 May; 108(5):716-20. PubMed ID: 9129221
[TBL] [Abstract][Full Text] [Related]
10. A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.
Hunzeker JT; Elftman MD; Mellinger JC; Princiotta MF; Bonneau RH; Truckenmiller ME; Norbury CC
J Immunol; 2011 Jan; 186(1):183-94. PubMed ID: 21098225
[TBL] [Abstract][Full Text] [Related]
11. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes.
Hjálmsdóttir Á; Bühler C; Vonwil V; Roveri M; Håkerud M; Wäckerle-Men Y; Gander B; Johansen P
Mol Pharm; 2016 Feb; 13(2):320-9. PubMed ID: 26704885
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration.
Schmidt ST; Olsen CL; Franzyk H; Wørzner K; Korsholm KS; Rades T; Andersen P; Foged C; Christensen D
Eur J Pharm Biopharm; 2019 Jul; 140():29-39. PubMed ID: 31055066
[TBL] [Abstract][Full Text] [Related]
13. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.
den Haan JM; Lehar SM; Bevan MJ
J Exp Med; 2000 Dec; 192(12):1685-96. PubMed ID: 11120766
[TBL] [Abstract][Full Text] [Related]
14. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
15. Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity.
Taneichi M; Ishida H; Kajino K; Ogasawara K; Tanaka Y; Kasai M; Mori M; Nishida M; Yamamura H; Mizuguchi J; Uchida T
J Immunol; 2006 Aug; 177(4):2324-30. PubMed ID: 16887993
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
Porgador A; Gilboa E
J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
[TBL] [Abstract][Full Text] [Related]
17. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens.
Gao J; Ochyl LJ; Yang E; Moon JJ
Int J Nanomedicine; 2017; 12():1251-1264. PubMed ID: 28243087
[TBL] [Abstract][Full Text] [Related]
18. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
19. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
20. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.
Schmidt ST; Khadke S; Korsholm KS; Perrie Y; Rades T; Andersen P; Foged C; Christensen D
J Control Release; 2016 Oct; 239():107-17. PubMed ID: 27574990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
